ES2151597T3 - Composiciones inmunogenicas de polisacaridos estreptococcicos del grupo a y procedimientos. - Google Patents

Composiciones inmunogenicas de polisacaridos estreptococcicos del grupo a y procedimientos.

Info

Publication number
ES2151597T3
ES2151597T3 ES95916479T ES95916479T ES2151597T3 ES 2151597 T3 ES2151597 T3 ES 2151597T3 ES 95916479 T ES95916479 T ES 95916479T ES 95916479 T ES95916479 T ES 95916479T ES 2151597 T3 ES2151597 T3 ES 2151597T3
Authority
ES
Spain
Prior art keywords
group
polisacarids
streptococcic
procedures
immunogenic compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95916479T
Other languages
English (en)
Inventor
Milan S Blake
John B Zabriskie
Joseph Y Tai
Francis Michon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
North American Vaccine Inc
Original Assignee
Rockefeller University
North American Vaccine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University, North American Vaccine Inc filed Critical Rockefeller University
Application granted granted Critical
Publication of ES2151597T3 publication Critical patent/ES2151597T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE PROPORCIONA UN NUEVO COMPUESTO INMUNOGENICO Y VACUNA, PROCESOS PARA PRODUCIRLOS Y METODOS DE INMUNIZACION CONTRA INFECCIONES Y TRASTORNOS CAUSADOS POR EL STREPTOCOCCI GRUPO A. LOS COMPUESTOS INCLUYEN POLISACARIDOS ESTREPTOCOCICOS DEL GRUPO A UNIDOS DE FORMA COVALENTE A PROTEINAS O LIPOSOMAS PARA FORMAR CONJUGADOS INMUNOGENICOS. EL METODO DE INMUNIZACION QUE SE DESCRIBE SE BASA EN LA ADMINISTRACION A UN INDIVIDUO DE UNA CANTIDAD INMUNOGENICA DE POLISACARIDOS DEL GRUPO A. ESTOS POLISACARIDOS PUEDEN ADMINISTRARSE COMO UNA VACUNA O POR SI MISMOS, UNIDOS A PROTEINAS O A LIPOSOMAS. ADICIONALMENTE LOS POLISACARIDOS DEL GRUPO A PUEDEN ASOCIARSE CON UN ADYUVANTE. ESTA INVENCION ES DE GRAN UTILIDAD PARA PROTEGER INMUNOGENICAMENTE DE FORMA ACTIVA Y PASIVA A AQUELLOS SECTORES DE LA POBLACION ESPECIALMENTE EN RIESGO DE CONTRAER INFECCIONES POR ESTE ESTREPTOCOCO COMO PUEDEN SER ADULTOS, MUJERES EMBARAZADAS, NIÑOS Y ADOLESCENTES.
ES95916479T 1994-04-21 1995-04-20 Composiciones inmunogenicas de polisacaridos estreptococcicos del grupo a y procedimientos. Expired - Lifetime ES2151597T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/231,229 US5866135A (en) 1994-04-21 1994-04-21 Group A streptococcal polysaccharide immunogenic compositions and methods

Publications (1)

Publication Number Publication Date
ES2151597T3 true ES2151597T3 (es) 2001-01-01

Family

ID=22868303

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95916479T Expired - Lifetime ES2151597T3 (es) 1994-04-21 1995-04-20 Composiciones inmunogenicas de polisacaridos estreptococcicos del grupo a y procedimientos.

Country Status (17)

Country Link
US (2) US5866135A (es)
EP (1) EP0754055B1 (es)
JP (1) JPH09512276A (es)
CN (1) CN1159064C (es)
AT (1) ATE196605T1 (es)
AU (1) AU709797B2 (es)
BR (1) BR9507400A (es)
CA (1) CA2188284C (es)
DE (1) DE69518978T2 (es)
DK (1) DK0754055T3 (es)
ES (1) ES2151597T3 (es)
FI (1) FI118514B (es)
GR (1) GR3034916T3 (es)
NO (1) NO321321B1 (es)
PL (1) PL181037B1 (es)
PT (1) PT754055E (es)
WO (1) WO1995028960A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US5846547A (en) * 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
AU761831B2 (en) * 1998-04-15 2003-06-12 Bioscience 2002 Llc Inhibition of xenoreactive antibodies
ATE459373T1 (de) * 1999-03-19 2010-03-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
US7256265B2 (en) 1999-12-03 2007-08-14 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
CA2413450C (en) * 2000-06-20 2014-02-18 Shire Biochem Inc. Streptococcus antigens
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
US20020192205A1 (en) * 2001-05-11 2002-12-19 Francis Michon Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group A and group C streptococci
WO2003015815A1 (en) * 2001-08-21 2003-02-27 The Brigham And Women's Hospital, Inc. Improved conjugate vaccines
AU2003252017A1 (en) * 2002-07-19 2004-02-09 The Regents Of The University Of California Methods and compositions for modulating agonist-induced downregulation of g protein-coupled receptors
US20040197845A1 (en) * 2002-08-30 2004-10-07 Arjang Hassibi Methods and apparatus for pathogen detection, identification and/or quantification
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
CA2692069C (en) * 2007-06-20 2016-10-18 Baxter Healthcare S.A. Modified polysaccharides for conjugate vaccines
EP2045201A1 (en) * 2007-10-02 2009-04-08 M T C - Macchine Trasformazione Carta S.r.l. Rewinding method and rewinding machine that carries out this method
NZ591633A (en) * 2008-09-17 2012-10-26 Novartis Ag Combination gas vaccines and therapeutics
CA2777837C (en) 2008-10-27 2017-07-11 Novartis Ag Purification method
JP5344558B2 (ja) * 2008-10-31 2013-11-20 国立大学法人 東京医科歯科大学 カチオン性ナノゲルを用いる粘膜ワクチン
MX2011004755A (es) 2008-11-05 2011-10-10 Wyeth Llc Composicion inmunogenica multicomponente para la prevencion de enfermedad estreptococica beta-hemolitica (bhs).
US20130149331A1 (en) * 2011-05-03 2013-06-13 Peng George Wang Rhamnose and forssman conjugated immunogenic agents
WO2013020090A2 (en) 2011-08-04 2013-02-07 The Regents Of The University Of California STREPTOCOCCAL GLcNAc-LACKING GLYCOPOLYPEPTIDES, CELL WALL CARBOHYDRATES, STREPTOCOCCUS VACCINES, AND METHODS FOR MAKING AND USING THEM
CN106606775A (zh) * 2015-10-27 2017-05-03 格里菲斯大学 脂质体a群链球菌疫苗
CN111093650B (zh) 2017-09-07 2024-03-01 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
AU2019210204B2 (en) * 2018-01-18 2024-05-16 EndoProtech, Inc. Treating microvascular dysfunction

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
ZA937034B (en) * 1992-09-24 1995-06-23 Brigham & Womens Hospital Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods

Also Published As

Publication number Publication date
FI964189L (fi) 1996-12-18
NO964413D0 (no) 1996-10-17
NO964413L (no) 1996-12-17
PT754055E (pt) 2001-02-28
CA2188284A1 (en) 1995-11-02
EP0754055B1 (en) 2000-09-27
US20050163808A1 (en) 2005-07-28
WO1995028960A1 (en) 1995-11-02
BR9507400A (pt) 1997-10-07
FI964189A0 (fi) 1996-10-18
CA2188284C (en) 2001-04-17
CN1149835A (zh) 1997-05-14
AU709797B2 (en) 1999-09-09
DE69518978T2 (de) 2001-03-15
DE69518978D1 (de) 2000-11-02
CN1159064C (zh) 2004-07-28
ATE196605T1 (de) 2000-10-15
US5866135A (en) 1999-02-02
FI118514B (fi) 2007-12-14
AU2296795A (en) 1995-11-16
GR3034916T3 (en) 2001-02-28
PL181037B1 (pl) 2001-05-31
JPH09512276A (ja) 1997-12-09
EP0754055A1 (en) 1997-01-22
US7332173B2 (en) 2008-02-19
PL316906A1 (en) 1997-02-17
NO321321B1 (no) 2006-04-24
DK0754055T3 (da) 2000-12-18

Similar Documents

Publication Publication Date Title
ES2151597T3 (es) Composiciones inmunogenicas de polisacaridos estreptococcicos del grupo a y procedimientos.
ES2157447T3 (es) Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio.
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
GT200200138A (es) Vacunacion en dosis unica con mycoplasma hyopneumoniae
BR9915988A (pt) Vacina para peptidase c5a estreptocócica
ES2059372T3 (es) Conjugados inmunogenos.
ES2074124T5 (es) Composicion en forma de una espuma que contiene acido 5-aminosalicilico para administracion intra-rectal.
CY1109286T1 (el) Σκευασμα τυπου φυραματος που περιλαμβανουν διοξειδιο πυριτιου
ES2121820T3 (es) Vacuna de conjugados de polisacaridos de neumococos.
FR2814958B1 (fr) Composition vaccinale
ES2162319T3 (es) Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer.
MA29678B1 (fr) Nouvelle methode de prevention ou de traitement d'une infection par m tuberculosis
ES2081531T3 (es) Composiciones farmaceuticas que contienen rifaximina para el tratamiento de infecciones vaginales.
SE8406538D0 (sv) Novel derivatives of purine
CY1108147T1 (el) Εμβολιο κατα των σεξουαλικως μεταδιδομενων νοσων
AR023535A1 (es) Nuevas composiciones.
PT1206189E (pt) Formulacoes para vacinas de rotavirus
ES2137310T3 (es) Vacuna contra una infeccion por streptococcus suis.
BRPI0416376A (pt) composições para a redução da colonização bacteriana e da invasão do snc e métodos de uso destes
NL300189I1 (nl) Acellulair vaccin.
ES2058100T3 (es) Vacuna combinada.
ES2059130T3 (es) Composiciones farmaceuticas que contienen ipriflavona, procedimiento para su preparacion y uso terapeutico relacionado.
ES2136064T3 (es) Vacunas de toxoide de pasteurella multocida.
BR9809381A (pt) Composição de vacina anti-helicobacter compreendendo um adjuvante do tipo th1
JP2023517684A5 (es)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 754055

Country of ref document: ES